Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676555 · ClinicalTrials.gov registry record
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
A clinical trial of Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2
- Enrollment target
- 2
- Study locations
NCT04676555 is a study of Relapsing Forms of Multiple Sclerosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04676555, a study of Relapsing Forms of Multiple Sclerosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
Conditions Studied
Interventions
- DRUG Ocrelizumab
- DRUG Ofatumumab
Study Locations (2)
Maryland
- Novartis Investigative Site - Lutherville
Victoria
- Novartis Investigative Site - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2021-10-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676555
The ClinicalTrials.gov registry entry for NCT04676555 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Forms of Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab is the first listed.
NCT04676555 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Victoria.
Frequently Asked Questions
What is clinical trial NCT04676555 about?
NCT04676555 is a clinical study titled "Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis". This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
What is the current status of trial NCT04676555?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2021-05-11. Estimated completion is 2021-10-21.
What conditions does trial NCT04676555 study?
This clinical trial studies the following conditions: Relapsing Forms of Multiple Sclerosis.
What interventions are being tested in trial NCT04676555?
The interventions under investigation include: Ocrelizumab (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT04676555?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04676555 being conducted?
This trial has 2 study locations across Maryland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Forms of Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.